Skip to main navigation Skip to search Skip to main content

Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with177Lu-DOTATATE

  • Eleonora Pelle
  • , Taymeyah Al-Toubah
  • , Ghassan El-Haddad
  • , Brian Morse
  • , Bhavana Konda
  • , Vineeth Sukrithan
  • , Jonathan Strosberg

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Lutetium-177 (177Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described. We investigated the potential for intestinal ischemia in177Lu-DOTATATE-treated patients. Methods: Clinical records were reviewed of patients with midgut NETs treated with177Lu-DOTATATE at the Moffitt Cancer Center between April 2018 and December 2022 and at The Ohio State University between December 2017 and October 2020. Results: Among the cases reviewed, we identified three patients who developed bowel ischemia/perforation shortly after their initial treatment with177Lu-DOTATATE. All patients had metastatic small bowel NET with prominent mesenteric mass encasing/obstructing the mesenteric vessels and preexisting symptoms of postprandial abdominal pain. Conclusion: Acute bowel ischemia may be a rare complication of PRRT in patients with mesenteric arterial or venous obstruction from mesenteric metastasis.

Original languageEnglish
Article numbere250033
JournalEndocrine Oncology
Volume5
Issue number1
DOIs
StatePublished - Jan 2025

Keywords

  • PRRT
  • bowel ischemia
  • mesenteric lesions
  • small bowel NET

Fingerprint

Dive into the research topics of 'Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with177Lu-DOTATATE'. Together they form a unique fingerprint.

Cite this